327 related articles for article (PubMed ID: 32380571)
1. Evolution of Systemic Therapy for Hepatocellular Carcinoma.
Finn RS; Zhu AX
Hepatology; 2021 Jan; 73 Suppl 1():150-157. PubMed ID: 32380571
[TBL] [Abstract][Full Text] [Related]
2. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
Rizzo A
Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
[No Abstract] [Full Text] [Related]
3. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
Rizzo A; Ricci AD; Brandi G
Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
[No Abstract] [Full Text] [Related]
4. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
5. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
Armstrong SA; He AR
Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Montella L; Palmieri G; Addeo R; Del Prete S
World J Gastroenterol; 2016 Jul; 22(27):6114-26. PubMed ID: 27468204
[TBL] [Abstract][Full Text] [Related]
7. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
Cheng AL
Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
[No Abstract] [Full Text] [Related]
8. [Targeted HCC therapies: the door has been opened!].
Rosmorduc O; Fartoux L
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969
[No Abstract] [Full Text] [Related]
9. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Hato T; Zhu AX; Duda DG
Immunotherapy; 2016; 8(3):299-313. PubMed ID: 26865127
[TBL] [Abstract][Full Text] [Related]
10. New systemic agents for hepatocellular carcinoma: an update 2020.
von Felden J
Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
13. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Chan LL; Chan SL
Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapies in hepatocellular carcinomas: recent results and future development].
Marijon H; Faivre S; Raymond E
Bull Cancer; 2009 May; 96(5):553-61. PubMed ID: 19467986
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?
Kapacee ZA; McNamara MG; de Liguori Carino N; Lamarca A; Valle JW; Hubner RA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt A):583-590. PubMed ID: 32303415
[TBL] [Abstract][Full Text] [Related]
16. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check.
Lee A; Lee FC
Front Med; 2020 Jun; 14(3):273-283. PubMed ID: 31863306
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
18. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Zhu AX
Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
[No Abstract] [Full Text] [Related]
19. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
Sharma R; Motedayen Aval L
Front Immunol; 2021; 12():652007. PubMed ID: 33790915
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib: where do we go from here?
Siegel AB; Olsen SK; Magun A; Brown RS
Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
